Verigraft AB
Verigraft AB is a Swedish clinical-stage biotechnology company developing personalized tissue-engineered grafts using proprietary decellularization and recellularization technology, eliminating transplant rejection and immunosuppression. Its lead product P-TEV targets chronic venous insufficiency in pivotal Phase II/III trials.
- Company typePrivate
- Founded2014
- HeadquartersGothenburg, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Verigraft AB does
Verigraft AB is a Swedish clinical-stage biotechnology company founded in 2014 (rooted in Karolinska Institute research) that develops personalized tissue-engineered transplants using a proprietary decellularization and recellularization platform. The technology removes donor cells and DNA from allogeneic tissue while preserving native matrix structure, then reconditions the scaffold with the patient's own biological material to produce grafts that resemble autologous tissue, eliminating transplant rejection risk and the need for lifelong immunosuppression. The lead product, P-TEV (Personalized Tissue-Engineered Vein), targets chronic venous insufficiency and is currently in pivotal Phase II/III clinical trials across Spain, the Netherlands, and Poland following positive Phase I/II TECVI-1 results (11 patients treated, 82% graft functionality at 3 months, 64% at 12 months, no graft occlusions or infections). The pipeline extends the platform to arteries (P-TEA), peripheral nerves (P-TENT), and heart valves (P-TEHV).
The company monetizes through future hospital-procurement sales of ATMP products, with planned EU and US market approval by 2028. Its go-to-market relies on direct engagement with vascular surgery departments, KOL relationships, medical conference presence, and CRO partnerships (TFS HealthScience for trial execution; BBG Advanced Therapies for US manufacturing readiness). Revenue is supplemented by license partnerships, exemplified by Korean Stem Cell Bank for South Korean market access. Verigraft has secured significant non-dilutive grant funding (cumulative EU Horizon 2020, Horizon Europe, Eurostars, and Vinnova grants exceeding EUR 8M) alongside equity raises, most recently a SEK 110M capital contribution and USD 10M financing from existing investors in February-March 2026. The technology is protected by 92 granted patents extending beyond 2039.
The company operates from Gothenburg, Sweden, with a wholly-owned Spanish subsidiary (Verigraft Iberia S.L.) supporting European clinical operations, and is backed by international investors from Europe, Asia, and the United States. Headcount is in the 10-50 range, with a leadership team comprising CEO Petter Björquist (PhD, ex-AstraZeneca, ex-Cellartis/Cellectis), CTO Raimund Strehl (ex-Cellartis), CFO Edvard Nordfors, and Chairman/CMO Jan Holgersson. The target market is anchored by chronic venous insufficiency, projected to reach USD 5.95B by 2034, with additional platform applications in cardiovascular surgery, dialysis access, peripheral nerve repair, and heart valve replacement.
Verigraft AB firmographics
Firmographics- Name
- Verigraft AB
- Legal name
- Verigraft AB
- Website
- https://verigraft.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Verigraft AB is a Swedish clinical-stage biotechnology company developing personalized tissue-engineered grafts using proprietary decellularization and recellularization technology, eliminating transplant rejection and immunosuppression. Its lead product P-TEV targets chronic venous insufficiency in pivotal Phase II/III trials.
- Ownership category
- akta.pro rank
Verigraft AB industry classification
Industry- Product category
- Regenerative Medicine and Tissue Engineering
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)
- akta.pro secondary industries
- Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ), Endovascular Aortic Repair (EVAR/TEVAR) & Aortic Grafts (HLAHAFAF), Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO)
Keywords
Where Verigraft AB is headquartered
LocationHeadquarters
- HQ city
- Gothenburg
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Verigraft AB business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Product Sales (Future): VERIGRAFT is a clinical-stage biotechnology company that will generate revenue through sale of personalized tissue-engineered medical products. The company is developing a pipeline of products including P-TEV (veins), P-TEA (arteries), P-TEN (nerves), and P-TEHV (heart valves). Currently pre-revenue with products in clinical development.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Verigraft AB product offering
Product offeringCore offering
VERIGRAFT develops and manufactures personalized tissue-engineered grafts using a proprietary decellularization and recellularization (DC/RC) platform that transforms donated allogeneic tissue into patient-specific transplants. Its lead product P-TEV (Personalized Tissue-Engineered Vein) targets chronic venous insufficiency and is currently in pivotal Phase II/III clinical trials, with additional pipeline products for arteries (P-TEA), nerves (P-TEN), and heart valves (P-TEHV).
Product overview
VERIGRAFT is a clinical-stage biotechnology company developing personalized tissue-engineered grafts using a proprietary platform that transforms donated allogeneic tissue into personalized transplants through decellularization (DC) and reconditioning/recellularization (RC) processes. The company's lead product is P-TEV (Personalized Tissue-Engineered Vein), currently in pivotal Phase II/III clinical trials for chronic venous insufficiency. The product portfolio includes P-TEA for arteries, P-TENT for peripheral nerves, and P-TEHV for heart valves. The technology eliminates transplant rejection risk and the need for lifelong immunosuppression. VERIGRAFT's pipeline spans from pre-clinical to clinical development stages, targeting vascular, cardiovascular, and neuronal diseases. The company also operates the P-TET production platform for industrialized tissue engineering.
Differentiator
Problem solved
Functional benefit
Brands
- P-TEV (Personalized Tissue Engineered Vein): Lead product for treatment of chronic venous insufficiency (CVI) - personalized tissue-engineered vein with functional valve
- P-TEATM (Personalized Tissue Engineered Arteries)
- P-TENTM (Personalized Tissue Engineered Nerves)
- P-TEHVTM (Personalized Tissue Engineered Heart Valves)
Quantifiable outcome
- 82% graft functionality at 3 months, 64% at 12 months in TECVI-1 trial
- +3 more outcomes
Companies that use Verigraft AB
Customer profileNamed customers3 records
Segments1 record
Ideal customer profiles2 records
Verigraft AB technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
Verigraft AB partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core, minor and major.
- BBG Advanced Therapies (subsidiary of BioBridge Global)coreCollaboration to support U.S. development and manufacturing readiness for VERIGRAFT's personalized tissue-engineered vein therapy (P-TEV). BBG AT provides donor vein sourcing, manufacturing, testing operations, and clinical trial preparation support in the United States. This collaboration represents strategic expansion into the U.S. market and builds on VERIGRAFT's existing European clinical experience.
- TFS HealthSciencecoreVERIGRAFT partnered with TFS HealthScience, a full-service global CRO, for the pivotal Phase II/III trial of P-TEV in patients with chronic venous insufficiency. TFS provides clinical research services across 40 countries, with specialized expertise in complex ATMP trials including manufacturing, logistics, and regulatory requirements. The partnership supports trial execution in Spain, Netherlands, and Poland.
- VISI-ON-BRAIN Doctoral NetworkminorVERIGRAFT participates as associated partner in EU-funded Horizon Europe Marie Skłodowska-Curie Doctoral Network (€4.5M EU contribution). Network focuses on advancing next-generation human in vitro and in silico approaches for complex brain disorders. VERIGRAFT contributes through collaboration and knowledge exchange.
- Korean Stem Cell Bank Co. LtdcoreVERIGRAFT's license partner in South Korea. Researchers from Korean Stem Cell Bank visited Gothenburg for hands-on experience in manufacturing of personalized grafts as part of ongoing collaboration to expand access to patient-specific tissue therapies in the Korean market.
- Chalmers University of TechnologyminorOngoing collaboration with Tissue Engineering course at Chalmers University. VERIGRAFT hosts annual student visits providing laboratory tours and hands-on insights. Collaboration strengthens connection between academia and industry and supports pipeline of future talent.
- PREPPER Consortium (Eurostars)majorVERIGRAFT leads PREPPER project (€1.2 million Eurostars funding) developing 3D-printed arterial grafts with partners Readily3D SA (Switzerland), RISE (Sweden), and Sahlgrenska University Hospital (Sweden). Project integrates advanced 3D printing, solution-blown fiber technology, and personalized tissue engineering to create customized vascular grafts.
- Sahlgrenska University HospitalmajorCollaboration on preclinical development of P-TEA (Personalized Tissue Engineered Arteries) and P-TEV clinical trials. Hospital provides clinical expertise and acts as partner in multiple CAMP and Vinnova-funded projects. Dr. Andrés García León serves as Principal Investigator for TECVI-1 trial.
- CCRM NordiccoreVERIGRAFT is a founding partner of CCRM Nordic, a non-profit organization providing infrastructure for Nordic stakeholders in advanced therapies. The collaboration aims to prepare for preclinical and clinical development of VERIGRAFT's platform portfolio. CCRM Nordic will provide necessary infrastructure for future development activities.
- TELEGRAFT Consortium (EU Horizon Europe)majorVERIGRAFT participates in EU-funded TELEGRAFT project (€4,352,522 total grant) to develop advanced arteriovenous graft for safe hemodialysis. Project involves 7 partners developing puncture-safe, anti-thrombotic graft with drug-releasing abilities and sensors for remote monitoring. Over 10% of population affected by chronic kidney disease.
- RISE Research Institutes of SwedenmajorMultiple collaborations with RISE including development of P-TEA platform, bioreactor technology optimization, GMP-compliant manufacturing processes, and 3D printing scaffold development. RISE provides research expertise and acts as project coordinator for various initiatives.
- Multiple Academic & Research PartnersmajorVERIGRAFT collaborates with Karolinska Institutet (company origin), University of Gothenburg, multiple Vinnova-funded project consortia including CAMP (Centre for Advanced Medical Products) and Advanced Therapies Vision Driven Health Project. Also involved in 4-DBR project for brain regeneration (ATMP for deep brain reconstruction).
Scale indicators8 records
Recent moves4 records
Expansion highlights6 records
Verigraft AB competitors and assessment
Company assessmentDirect peers
- Organogenesis Holdings: Commercial-stage regenerative medicine company developing advanced wound care and surgical biologics. Comparable to Verigraft in regenerative medicine focus and tissue-engineered product approach, though focused on skin/wound care rather than vascular grafts.
- Tissue Regenix Group: UK-based regenerative medicine company using decellularization technology (dCELL) for tissue engineering. Highly comparable to Verigraft's core decellularization/recellularization approach across vascular, cardiac, and soft tissue applications.
- Humacyte: Direct peer developing tissue-engineered vascular grafts using a similar regenerative medicine platform. Humacyte's bioengineered blood vessels (BioVascular Pancreas, HapMay) target vascular disease and represent the most directly comparable technology and clinical-stage approach to Verigraft's P-TEV.
- Cytograft Tissue Engineering: Tissue engineering company developing cell-based vascular grafts (Lifeline graft) for hemodialysis access. Direct competitor to Verigraft's TELEGRAFT project for dialysis vascular grafts using a similar personalized tissue-engineered approach.
- MiMedx Group: Commercial-stage regenerative medicine company using placental tissue allografts for wound care, surgical, and orthopedic applications. Comparable to Verigraft in the broader regenerative medicine space, though focused on different tissue types and clinical applications.
Broad incumbents
- Mesoblast: Commercial-stage regenerative medicine company developing mesenchymal stem cell therapies for inflammatory and cardiovascular diseases including chronic heart failure. Comparable as a larger, more advanced player in the cell therapy and regenerative medicine space with overlapping cardiovascular indications.
Emerging players
- Athersys: Clinical-stage cell therapy company developing MultiStem cell therapy for inflammatory, neurological, and cardiovascular indications. Comparable to Verigraft as a clinical-stage advanced therapy company developing novel regenerative approaches, though using stem cells rather than tissue engineering.
- Novadip Biosciences: Belgian clinical-stage regenerative medicine company developing tissue-engineered bone and skin products for severe tissue defects. Comparable to Verigraft as a European clinical-stage ATMP developer with platform technology for multiple tissue types.
- Pluristem Therapeutics: Clinical-stage cell therapy company developing placenta-derived cell therapies for peripheral artery disease and other vascular indications. Comparable to Verigraft's PAD application with P-TEA, though using cell therapy rather than tissue-engineered grafts.
- Hemostemix: Clinical-stage cell therapy company developing blood-derived stem cell therapies for critical limb ischemia and heart disease. Comparable to Verigraft's vascular applications (PAD, CVI) using autologous cell-based regenerative approaches.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Verigraft AB social profiles
Digital presenceVerigraft AB financial estimates
Financial estimateRevenue estimate
Valuation estimate
Verigraft AB leadership team
Management profileNumber of profiles
Profiles1 record
Verigraft AB subsidiaries and ownership
Company hierarchySubsidiaries1 record
Verigraft AB funding detail
Funding detailFunding overview
Funding rounds5 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Verigraft AB M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Verigraft AB
What does Verigraft AB do?
VERIGRAFT develops and manufactures personalized tissue-engineered grafts using a proprietary decellularization and recellularization (DC/RC) platform that transforms donated allogeneic tissue into patient-specific transplants. Its lead product P-TEV (Personalized Tissue-Engineered Vein) targets chronic venous insufficiency and is currently in pivotal Phase II/III clinical trials, with additional pipeline products for arteries (P-TEA), nerves (P-TEN), and heart valves (P-TEHV).
Is Verigraft AB a public or private company?
Verigraft AB is a private company. It is classified as venture growth investor backed and is currently operating.
When was Verigraft AB founded?
Verigraft AB was founded in 2014. It employs 11 to 50 people.
Where is Verigraft AB based?
Verigraft AB is headquartered in Gothenburg, Sweden, in the Europe region.
How does Verigraft AB make money?
One revenue line is on record: product Sales (Future).
Who are Verigraft AB's main competitors?
Direct peers on record are Organogenesis Holdings, Tissue Regenix Group, Humacyte, Cytograft Tissue Engineering and MiMedx Group. Mesoblast is listed as a broad incumbent. Emerging players are Athersys, Novadip Biosciences, Pluristem Therapeutics and Hemostemix.
Does Verigraft AB have an API?
No public API is recorded for Verigraft AB.
What industry is Verigraft AB in?
Verigraft AB's product category is Regenerative Medicine and Tissue Engineering. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAAAGAJ, Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis). Its NAICS code is 325414 and its SIC code is 3841.